Related Experiment Video
Updated: Jun 10, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
Rare ALK-IR (Intergenic Region) Rearrangement in a Patient with Non-Small Cell Lung Cancer: A Case Report
Qingtao Ni1, Chi Pan2, Guangzhi Sun1
1Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, 225300, China.
Introduction:
Non-small cell lung cancer (NSCLC) accounts for most lung cancer cases, with anaplastic lymphoma kinase (ALK) rearrangement being a key driver in some instances. The identification of oncogenic drivers in lung cancer has transformed the therapeutic landscape of NSCLC management. Developing and using specific ALK inhibitors have markedly improved clinical outcomes in patients with ALK-positive tumors.
Case Description:
A 42-year-old male presented with hoarseness and was diagnosed with lung adenocarcinoma through lymph node biopsy. A positron emission tomography-computed tomography (PET-CT) revealed a right upper lobe mass with extensive nodal metastases. Immunohistochemistry confirmed ALK positivity, and next-generation sequencing identified a novel ALK-IR (intergenic region) rearrangement (19.09% abundance), along with mutations in tumor protein 53 (TP53) and cyclin-dependent kinase inhibitor 2A (CDKN2A). To our knowledge, this is the first report of an ALK-IR rearrangement in NSCLC. The patient was treated with crizotinib (250 mg twice daily), achieving partial remission with symptom resolution and no adverse effects over 17 months.
Conclusion:
This first documented case demonstrates the therapeutic efficacy of crizotinib in ALK-IR rearranged NSCLC, emphasizing the importance of comprehensive molecular profiling in guiding precision oncology.
Insights
This case study reports the first instance of an anaplastic lymphoma kinase (ALK) intergenic region (IR) rearrangement in non-small cell lung cancer (NSCLC). Crizotinib treatment led to significant remission in this patient.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Anaplastic lymphoma kinase (ALK) rearrangements are key oncogenic drivers in a subset of NSCLC cases.
- ALK inhibitors have significantly improved outcomes for patients with ALK-positive NSCLC.
More Related Videos
Related Concept Videos
Non-LTR Retrotransposons
lncRNA - Long Non-coding RNAs
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...

